Apr 03, 2017 12:03 pm UTC| Business
iTeos Therapeutics to Present Data for Novel A2A Receptor Antagonist at American Association for Cancer Research Annual Meeting Gosselies, Belgium - April 3, 2017 -- iTeos Therapeutics SA, a biotechnology company...
Apr 03, 2017 12:03 pm UTC| Business
iTeos Therapeutics to Present Data for Novel A2A Receptor Antagonist at American Association for Cancer Research Annual Meeting Gosselies, Belgium - April 3, 2017 -- iTeos Therapeutics SA, a biotechnology company...
Apr 03, 2017 12:03 pm UTC| Business
iTeos Therapeutics to Present Data for Novel A2A Receptor Antagonist at American Association for Cancer Research Annual Meeting Gosselies, Belgium - April 3, 2017 -- iTeos Therapeutics SA, a biotechnology company...
Apr 03, 2017 12:03 pm UTC| Business
AUSTIN, Texas, April 03, 2017 -- XBiotech Inc. (NASDAQ:XBIT) announced top-line results today from its double-blind, placebo-controlled, phase I-II study evaluating the safety and efficacy of its FDA Fast Tracked true...
Apr 03, 2017 12:03 pm UTC| Business
AUSTIN, Texas, April 03, 2017 -- XBiotech Inc. (NASDAQ:XBIT) announced top-line results today from its double-blind, placebo-controlled, phase I-II study evaluating the safety and efficacy of its FDA Fast Tracked true...
Apr 03, 2017 12:03 pm UTC| Business
AUSTIN, Texas, April 03, 2017 -- XBiotech Inc. (NASDAQ:XBIT) announced top-line results today from its double-blind, placebo-controlled, phase I-II study evaluating the safety and efficacy of its FDA Fast Tracked true...
Apr 03, 2017 12:03 pm UTC| Business
AUSTIN, Texas, April 03, 2017 -- XBiotech Inc. (NASDAQ:XBIT) announced top-line results today from its double-blind, placebo-controlled, phase I-II study evaluating the safety and efficacy of its FDA Fast Tracked true...